Toxicity data: why? [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2013-09-03 15:02 (4676 d 21:24 ago) – Posting: # 11416
Views: 11,936

Hi Miityri,

❝ Are new requirements in this draft (see above) closer to EMEA GL?


Since EMA doesn’t require anything – yes, closer. ;-)

I still fail to understand this requirement at all. Animal models are – only models. The innovator’s drug is on the market for years – administered to humans (the target species), not animals (a model species). Pharmacovigilance data show that the drug is safe or – more precisely – its benefits outweigh its risks. These safety data are available to regulators. It is beyond my intellectual reach how short term toxicity data in say 24 Sprague Dawley rats could give more information than ADRs collected in millions of patient-years.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
133 visitors (1 registered, 132 guests [including 18 identified bots]).
Forum time: 12:27 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5